<div id="readability-page-1"><p>Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of &#34;Moderate Buy&#34; from the eight ratings firms that are  covering the stock, MarketBeat reports. One research analyst  has rated the stock with a sell rating, one  has assigned  a hold rating, five have issued  a buy rating and one  has given a strong buy rating to  the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $18.3333.</p><div><p><span></span><span>Get <strong>Candel Therapeutics</strong> alerts:</span></p></div><ul><li>Unusually High Volume Points to Upside in These Stocks</li></ul><p>CADL has been the topic of several recent research reports. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Monday, September 29th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Candel Therapeutics in a research note on Wednesday, October 8th. Citigroup decreased their target price on Candel Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 14th. Lifesci Capital initiated coverage on Candel Therapeutics in a report on Tuesday, October 21st. They set an &#34;outperform&#34; rating and a $16.00 price target on the stock. Finally, Wall Street Zen lowered Candel Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th.</p><p><b>Check Out Our Latest Research Report on CADL</b></p><h2>Institutional Trading of Candel Therapeutics</h2><p>Hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC lifted its stake in  Candel Therapeutics by 19.9% in the second quarter. Acorn Capital Advisors LLC now owns 2,580,517 shares of the company's stock worth $13,057,000 after acquiring an additional 428,265 shares during the last quarter.  Vanguard Group Inc. raised its holdings in shares of  Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company's stock valued at $10,236,000 after purchasing an additional 219,563 shares in the last quarter.  Geode Capital Management LLC lifted its position in shares of  Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company's stock worth $4,575,000 after purchasing an additional 216,509 shares during the last quarter.  Halter Ferguson Financial Inc. grew its stake in shares of  Candel Therapeutics by 12.0% during the second quarter. Halter Ferguson Financial Inc. now owns 776,516 shares of the company's stock worth $3,929,000 after purchasing an additional 83,363 shares in the last quarter.  Finally, Tanager Wealth Management LLP acquired a new position in shares of  Candel Therapeutics during the second quarter worth $995,000. Institutional investors and hedge funds own  13.93% of the company's stock. </p><h2>Candel Therapeutics Stock Performance</h2><p>Shares of Candel Therapeutics stock opened at $5.65 on Friday. The stock has a market capitalization of $310.19 million, a price-to-earnings ratio of -9.91 and a beta of -0.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The business has a 50-day moving average of $5.27 and a 200 day moving average of $5.52. Candel Therapeutics has a 12 month low of $4.25 and a 12 month high of $13.68. </p><p>Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04).  As a group, sell-side analysts forecast that  Candel Therapeutics will post -1.47 earnings per share for the current year. </p><h2>About Candel Therapeutics</h2> (Get Free Report)<p>Candel Therapeutics <span>NASDAQ: CADL<span></span></span> is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.  </p><p>In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.</p><h2>See Also</h2><ul><li>Five stocks we like better than Candel Therapeutics</li><li>GOLD ALERT</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>Bombshell Exposé on China Strikes</li><li>Do not delete, read immediately</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FETA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Candel Therapeutics Right Now?</h2><p>Before you consider Candel Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.</p><p>While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CADL

<p>Candel Therapeutics, Inc. (NASDAQ:CADL) has received a consensus rating of "Moderate Buy" from eight brokerages. The stock has one sell, one hold, five buy, and one strong buy rating. The average 12-month target price is $18.33. Recent reports include a reaffirmed buy rating with a $23 target from HC Wainwright and a lowered target from Citigroup. Candel's stock opened at $5.65, with a market cap of $310.19 million. The company reported a quarterly EPS of ($0.21), missing estimates. Candel focuses on developing oncolytic viral therapies for solid tumors.</p>

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages